Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kelonia Therapeutics

Request full access

In vivo CAR-T therapies via targeted gene delivery

Boston, United StatesFounded 2020Biotech & Life Sciences

About Kelonia Therapeutics

Kelonia Therapeutics is a clinical-stage biotechnology company developing genetic medicines that reprogram a patient's own immune cells inside the body. Its work centres on in vivo CAR-T cell therapy, an approach intended to remove the need to harvest, engineer and reinfuse cells outside the body, which is how currently marketed cell therapies are made.

The company's platform uses specially engineered viral particles that deliver genetic material precisely to targeted cell types. Once delivered, the genetic payload instructs T cells to produce a new cancer-fighting receptor, turning them into CAR-T cells directly in the patient. Because the treatment is designed as a one-time intravenous infusion that does not require chemotherapy-based preconditioning, it aims to offer an off-the-shelf alternative that could be administered more widely than personalised ex vivo cell therapies, which are largely limited to specialised academic medical centres.

Kelonia's lead programme, KLN-1010, is an in vivo anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma, a blood cancer, and is being evaluated in the Phase 1 inMMyCAR study. Beyond multiple myeloma, the delivery technology is being explored for other haematological cancers and potentially solid tumours, and has also been applied to immuno-oncology research programmes with industry partners.

The company describes a patient-first mission focused on making potentially life-saving genetic medicines accessible to more patients. Kelonia now operates as part of Eli Lilly and Company.

Source: Dealroom company data

Kelonia Therapeutics in the Boston ecosystem

Live from Dealroom

The Kelonia Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Series B and later2 investors entered at this stage

  • French National Centre for Scientific Research - CNRS
  • Massachusetts Institute of Technology
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$291k

6 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Kelonia Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.